A Novel Jaspine BCeramide Hybrid Modulates Sphingolipid Metabolism |
| |
| Authors: | Virginie Garcia Pauline Le?Faouder Aude Dupuy Thierry Levade Stéphanie Ballereau Yves Génisson |
| |
| Institution: | 1. INSERM UMR1037, CRCT (Centre de Recherches en Can?erolgie de Toulouse), Oncopole de Toulouse, 2, avenue Hubert Curien, CS 53717, 31037 Toulouse cedex 1;2. Lipidomic Core Facility, MetaToul platform, UMR1048 INSERM‐Université Paul Sabatier‐Toulouse III, CHU Rangueil, BP, FR‐84225, Toulouse;3. LSPCMIB, UMR‐5068, CNRS, Université de Toulouse, UPS, FR‐31062, Toulouse, (phone: +33‐561‐556299;4. fax: +33‐561‐556011) |
| |
| Abstract: | A new sphingolipid hybrid molecule was designed to assemble, within a tail‐to‐tail double‐chain structure, the ceramide hydrophilic moiety and the tetrahydrofuran pharmacophore of jaspine B, a natural product known to interfere with sphingolipid metabolism. This compound was prepared through acylation of sphingosine with a jaspine B derivative bearing a COOH group in the terminal position of the aliphatic backbone. This new hybrid molecule was evaluated for its capacities to affect melanoma cell viability and sphingolipid metabolism. While retaining the cytotoxicity of ceramide itself, this compound was shown to lower the sphingomyelin cellular levels and significantly enhance the production of sphingosine‐1‐phosphate, thus representing a novel sphingolipid metabolism modulator. |
| |
| Keywords: | Jaspine B Pachastrissamine Ceramide Sphingolipid Hydrid molecules |
|
|
